December 2024 – Page 18

Limited Access to Mounjaro: England’s NHS Rolls Out Obesity Drug with Phased Approach

6 months ago talkbio0Tagged Access, England, Mounjaro, Nance-Horan syndrome, Obesity, Phase, rollout, Weight Loss Medication

Mounjaro, obesity drug, NHS England, limited access, phased rollout, weight loss medication, tirzepatide.

Zepbound Outperforms Wegovy in Weight Loss Trial, Offering Superior Efficacy

6 months ago talkbio0Tagged Clinical Trials, Eli, Eli Lilly, Nordisk, Obesity, semaglutide, Wegovy, Zepbound

Zepbound, Wegovy, weight loss, tirzepatide, semaglutide, clinical trial, obesity medication, Eli Lilly, Novo Nordisk

GSK Partners with Muna Therapeutics to Unlock Novel Alzheimer’s Treatments

6 months ago talkbio0Tagged Alzheimer 's disease, Drug Discovery, MiND-MAP platform, Muna, Neurodegenerative Disorders, SmithKline Beecham, spatial transcriptomics, targets

Muna Therapeutics, GSK, Alzheimer’s disease, neurodegenerative diseases, spatial transcriptomics, MiND-MAP platform, drug discovery, therapeutic targets.

Eli Lilly Invests $3 Billion in Wisconsin Manufacturing Expansion to Meet Growing Demand for Diabetes and Obesity Medicines

6 months ago talkbio0Tagged Diabetes, Eli, Eli Lilly, expansion, Investments, Manufacturing, Obesity, Surgical construction, Wisconsin

Eli Lilly, Wisconsin, manufacturing expansion, diabetes, obesity, pharmaceuticals, investment, job creation

Protara’s TARA-002 Cell Therapy Shows Exceptional Promise in Treating Non-Muscle Invasive Bladder Cancer

6 months ago talkbio0Tagged BCG-Naïve, BCG-Unresponsive, Carcinoma of urinary bladder, invasive, Cell Therapy, Clinical Trials, Lyophilized Inactivated Group A Streptococcus TARA-002, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Phase 2, Protara Therapeutics

Protara Therapeutics, TARA-002, Non-Muscle Invasive Bladder Cancer (NMIBC), Phase 2 ADVANCED-2 trial, Cell therapy, BCG-Unresponsive, BCG-Naïve

Nuvig Therapeutics Secures $161M Series B Financing to Advance Immunomodulatory Portfolio

6 months ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, Immunomodulating Agents, Nuvig, NVG-2089, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Series B financing

Nuvig Therapeutics, Series B financing, immunomodulatory drugs, autoimmune diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), NVG-2089, clinical trials.

GSK Partners with Muna Therapeutics to Advance Alzheimer’s Treatment Research

6 months ago talkbio0Tagged Alzheimer 's disease, Collaboration, drug research, genetic code analysis, Muna, Neurodegenerative Disorders, Neuroscience discipline, SmithKline Beecham

GSK, Muna Therapeutics, Alzheimer’s disease, neurodegenerative diseases, drug research, genetic code analysis, neuroscience, collaboration.

FDA Approves Imfinzi for Limited-Stage Small Cell Lung Cancer, Marking First Systemic Immunotherapy for LS-SCLC

6 months ago talkbio0Tagged ADRIATIC, Approved, Breakthrough Therapy, durvalumab, Identifier, Imfinzi, Limited-stage, LS-SCLC, Phase 3 Clinical Trials, Priority Review, Systemic Immunotherapy, United States Food and Drug Administration

Imfinzi (durvalumab), Limited-stage small cell lung cancer (LS-SCLC), FDA approval, Systemic immunotherapy, ADRIATIC Phase III trial, Breakthrough Therapy Designation, Priority Review